DIA, Horsham, PA USA
Mar 19 2012 8:30AM - Mar 20 2012 2:30PM
Discuss proven strategies to achieve regulatory compliance for the development of biologics.
What you will learn
Difference between traditional biologics and biotechnology products
Regulatory needs and requirements for biologics
Unique aspects in the development of specific biologics such as vaccines and gene therapy
Differences in how CBER views product development compared to CDER
Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.